

The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding.

Courtney Mycroft-West ^{#1}, Dunhao Su^{#2}, Stefano Elli ^{#3}, Scott Guimond ⁴, Gavin Miller ⁵, Jeremy Turnbull ², Edwin Yates ², Marco Guerrini ^{*3}, David Fernig ^{*2}, Marcelo Lima ^{*1} and Mark Skidmore ^{*1§}.

1. Molecular & Structural Biosciences, School of Life Sciences, Keele University, Newcastle-Under-Lyme, Staffordshire, ST5 5BG, United Kingdom.
2. Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Crown Street, Liverpool, L69 7ZB, United Kingdom.
3. Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni, Via G. Colombo 81, 20133, Milan, Italy.
4. School of Medicine, Keele University, Newcastle-Under-Lyme, Staffordshire, ST5 5BG, United Kingdom.
5. School of Chemistry, Keele University, Newcastle-Under-Lyme, Staffordshire, ST5 5BG, United Kingdom.

§ Corresponding author: m.a.skidmore@keele.ac.uk. Tel: +44 (0)1782 733945

Joint first # & senior * authors

Abstract

Many pathogens take advantage of the dependence of the host on the interaction of hundreds of extracellular proteins with the glycosaminoglycans heparan sulfate to regulate homeostasis and use heparan sulfate as a means to adhere and gain access to cells. Moreover, mucosal epithelia such as that of the respiratory tract are protected by a layer of mucin polysaccharides, which are usually sulfated. Consequently, the polydisperse, natural products of heparan sulfate and the allied polysaccharide, heparin have been found to be involved and prevent infection by a range of viruses including S-associated coronavirus strain HSR1. Here we use surface plasmon resonance and circular dichroism to measure the interaction between the SARS-CoV-2 Spike S1 protein receptor binding domain (SARS-CoV-2 S1 RBD) and heparin. The data demonstrate an interaction between the recombinant surface receptor binding domain and the polysaccharide. This has implications for the rapid development of a first-line therapeutic by repurposing heparin and for next-generation, tailor-made, GAG-based antivirals.

Key Words: heparin; coronavirus; SARS-CoV-2; COVID-19; nCoV-19; Spike; S1, RBD; circular dichroism; surface plasmon resonance; molecular modelling.

Introduction

Heparin, the second most widely used drug by weight globally, is formulated as a polydisperse, heterogenous natural product. Unfractionated heparin, low molecular weight heparins and heparinoids are clinically approved as anticoagulants / thrombotic with excellent safety, stability, bioavailability and pharmacokinetic profiles. Crucially, heparin and its derivatives, some of which lacking significant anticoagulant activity ¹, are an under-exploited antiviral drug class, despite possessing broad-spectrum activity against a multitude of distinct viruses, including *coronaviridae* and SARS-associated coronavirus strain HSR1 ², in addition to flaviviruses ^{3,4}, herpes ⁵, influenza ⁶ and HIV ^{7,8}.

Traditional drug development processes are slow and ineffective against emerging public health threats such as the current SARS-CoV-2 coronavirus outbreak which makes the repurposing of existing drugs a timely and attractive alternative. Heparin, a well-tolerated anticoagulant pharmaceutical, has been used safely in medicine for over 80 years and alongside its anticoagulant activities, its ability to prevent viral infection, including *coronaviridae*, has been described¹. Furthermore, the closely related glycosaminoglycan (GAG) member, heparan sulfate (HS), is known to bind CoV surface proteins and to be used by coronavirus for its attachment to target cells⁹.

Currently, there are no commercially available medicinal products designed to treat and/or prevent infections associated with the new SARS-CoV-2 coronavirus outbreak. Here, we describe preliminary tests for the ability of the SARS-CoV-2 S1 RBD to bind heparin, an important prerequisite for the underpinning research related to the development of SARS-CoV-2 heparin-based therapeutic.

Methods & Materials

2.1 Recombinant expression of SARS-CoV-2 S1 RBD

Residues 330–583 of the SARS-CoV-2 Spike Protein (GenBank: MN908947) were cloned upstream of a N-terminal 6XHisTag in the pRSETA expression vector and transformed into SHuffle® T7 Express Competent *E. coli* (NEB, UK). Protein expression was carried out in MagicMedia™ *E. coli* Expression Media (Invitrogen, UK) at 30°C for 24 hrs, 250 rpm. The bacterial pellet was suspended in 5 mL lysis buffer (BugBuster Protein Extraction Reagent, Merck Millipore, UK; containing DNase) and incubated at room temperature for 30 mins. Protein was purified from inclusion bodies using IMAC chromatography under denaturing conditions. On-column protein refolding was performed by applying a gradient with decreasing concentrations of the denaturing agent (6-0 M Urea). After extensive washing, protein was eluted using 20 mM NaH₂PO₄, pH 8.0, 300 mM NaCl, 500 mM imidazole. Fractions were pooled and buffer-exchanged to phosphate-buffered saline (PBS; 140 mM NaCl, 5 mM NaH₂PO₄, 5 mM Na₂HPO₄, pH 7.4; Lonza, UK) using a PD-10 desalting column (GE Healthcare, UK). Recombinant protein was stored at -20°C until required.

2.2 Secondary structure determination of SARS-CoV-2 S1 RBD by circular dichroism spectroscopy

The circular dichroism (CD) spectra of the SARS-CoV-2 S1 RBD in PBS was recorded using a J-1500 Jasco CD spectrometer, Spectral Manager II software and a 0.2 mm pathlength quartz cuvette (Hellma, USA) scanning at 100 nm.min⁻¹ with a 1 nm resolution throughout the range of $\lambda = 190 - 260$ nm. All spectra obtained were the mean of five independent scans post calibration with camphorsulfonic acid. SARS-CoV-2 S1 RBD was buffer-exchanged (prior to spectral analysis) using a 5 kDa Vivaspin centrifugal filter (Sartorius, Germany) at 12,000 g, thrice. Collected data was analysed with Spectral Manager II software prior to processing with GraphPad Prism 7, using a second order polynomial smoothing through 21 neighbours. Secondary structural prediction was calculated through the BeStSel analysis server ¹⁰. To ensure the CD spectral change of SARS-CoV-2 S1 RBD in the presence of heparin was not altered owing to the addition of the heparin alone, which is known to possess CD spectra at high concentrations ^{11,12} a differential spectrum was analysed. The theoretical, summative CD spectra was confirmed to differ from the observed experimental CD spectra, thereby indicating that the change in the CD spectra compared to that of SARS-CoV-2 S1 RBD alone is a result of a conformational change upon binding to porcine mucosal heparin (Leo Pharma, UK).

2.3 Surface Plasmon Resonance determination of SARS-CoV-2 S1 RBD binding to unfractionated heparin.

Human FGF2 was produced as described by Duchesne *et al.* ¹³. Porcine mucosal heparin was biotinylated at the reducing end using hydroxylamine biotin (ThermoFisher, UK) as described by Thakar *et al.* ¹⁴. Heparin (20 μ L 50 mg/mL) was reacted with 20 μ L hydroxylamine-biotin in 40 μ L 300 mM aniline (Sigma-Aldrich, UK) and 40 μ L 200 mM acetate pH 6 for 48 h at 37 °C. Free biotin was removed by gel-filtration chromatography on Sephadex G25 (GE LifeSciences, UK).

A P4SPR, multi-channel Surface Plasmon Resonance (SPR) instrument (Affinté Instruments; Montréal, Canada) was utilised with a gold sensor chip that was plasma cleaned prior to derivatization. A self-assembled monolayer of mPEG thiol and biotin mPEG was formed by incubating the chip in a 1 mM solution of these reagents at a 99:1 molar ratio in ethanol for 24 hrs ¹⁵. The chip was rinsed with ethanol and placed into the instrument. PBS (1X) was used as the running buffer for the three sensing and a fourth background channel at 500 μ L.min⁻¹, using an Ismatec pump. Twenty micrograms of streptavidin (Sigma, UK; 1mL in PBS) were injected over the four sensor channels. Subsequently, biotin-heparin (1 mL) was injected over the three sensing channels.

In binding experiments, the ligate was injected over the three sensing channels, diluted to the concentration indicated in the figure legends at 500 μ L.min⁻¹. Sensor surfaces with bound FGF2 were regenerated by a wash with 2 M NaCl, whereas 20 mM HCl was used to regenerate surfaces with bound SARS-CoV-2 S1 RBD as 2 M NaCl was ineffective to disrupt binding. Background binding to the underlying streptavidin bound to the mPEG/biotin mPEG self-assembled monolayer was determined by injection over the control channel. Responses are reported as the change in plasmon

resonance wavelength, in nm and for the three control channels represent their average response.

Results

3.1 Surface Plasmon Resonance binding studies.

FGF2, a well characterised heparin-binding protein was used to test the successful functionalization of the three sensing channels with biotin-heparin. Injection of 1 mL 100 nM FGF2 over the sensing channels elicited a significant response (Fig. 1A, injection between the red arrows). However, 100 nM FGF2 elicited no response in the control channel, functionalized solely with streptavidin (not shown). The bound FGF2 was removed by a wash with 2 M NaCl, as done previously for the IASys optical biosensor ¹⁶.

When 65 nM SARS-CoV-2 S1 RBD was injected over the three sensing channels, there was an initial decrease in signal, followed by an increase, indicative of binding (Fig. 1B between red arrows). The initial decrease was due to a slightly lower refractive index of the SARS-CoV-2 S1 RBD protein solution compared to the PBS of the running buffer, which caused a negative bulk shift. This is demonstrated by the injection of 65 nM solution over the control channel, functionalized with just streptavidin, where there was a decrease in response, followed by a return to baseline when the channel was returned to running buffer (Fig. 1C, between red arrows). These data demonstrate that the SARS-CoV-2 S1 RBD protein binds specifically to heparin immobilised through its reducing-end and fails to bind to the underlying streptavidin / ethyleneglycol surface.

3.2 Secondary structure determination of SARS-CoV-2 S1 RBD protein by circular dichroism spectroscopy

Circular dichroism (CD) spectroscopy detects changes in protein secondary structure that occur in solution using UV radiation. Upon binding, conformational changes are detected and quantified using spectral deconvolution ¹⁷. Indeed, SARS-CoV-2 S1 RBD underwent conformational change in the presence of heparin (Figure 2). Combined, Helix content increased by 4.8% and global beta-sheet content decreased by 4.4%. The observed changes further demonstrate that the SARS-CoV-2 S1 RBD interacts with heparin in aqueous solution of physiological significance, whereby the major changes induced by heparin are those associated with antiparallel and helix content.

Basic amino acids are known to dictate the binding between proteins and heparin. With that in mind, primary sequence analysis of the expressed protein domain and analysis of the modelled SARS-CoV-2 S1 RBD structure (Figure 3) shows that there are several potential heparin binding sites and, more importantly, that these patches of basic amino acids are exposed on the protein surface.




Figure 1. Interaction of FGF2 and Spike RBD with immobilised heparin. Reducing-end biotinylated heparin was immobilised on a streptavidin functionalized P4SPR sensor surface. PBS running buffer flow rate was $500 \mu\text{L}\cdot\text{min}^{-1}$. The data for the three sensing channels are reported as an average response. Protein injections are delimited by the red arrows. **A** Injection of 100 nM FGF2. **B** 64 nM S1 RBD protein. **C** 64 nM S1 RBD protein over a streptavidin surface (no heparin functionalization).




Figure 2. The structural change of the SARS-CoV-2 S1 RBD observed in the presence of heparin by circular dichroism (CD) spectroscopy. (A) CD spectra of 200 µg/mL spike 1 alone (purple) or with 30 µg heparin (orange) in phosphate buffered saline pH 7.4. Theoretical sum of spike 1 alone and 30 µg of heparin (control) if no interaction was observed (black). **(B)** Δ secondary structure (%) of (A). A 2.4% increase in helix and 2.2% decrease in antiparallel secondary structural features were calculated (BestSel) for the observed spectrum compared to that of the theoretical, summative spectrum of the SARS-CoV-2 S1 RBD in the presence of heparin.




Figure 3. SARS-CoV-2 S1 RBD protein model. Basic amino acids that are solvent accessible on the surface are indicated (dark blue); these can be observed to form a continuous patch.

Discussion and Conclusion

The rapid spread of SARS-CoV-2 represents a significant challenge to global health authorities and, as there are no currently approved drugs to treat, prevent and/or mitigate its effects, repurposing existing drugs is both a timely and appealing strategy. Heparin, a well tolerated anticoagulant drug, has been used successfully for over 80 years with limited and manageable side effects. Furthermore, heparin belongs to a unique class of pharmaceuticals that has effective antidotes available, which makes its use safer.

Studying SARS-CoV-2 Spike protein structure and behaviour in solution is a vital step for the development of effective therapeutics against SARS-CoV-2. Here, the ability of the SARS-CoV-2 S1 RBD to bind pharmaceutical heparin has been studied using spectroscopic techniques in concert with molecular modelling. The data show that SARS-CoV-2 S1 RBD binds to heparin and that upon binding, a significant structural change is induced. Moreover, moieties of basic amino acid residues, known to constitute heparin binding domains, are solvent accessible on the SARS-CoV-2 S1 RBD surface and form a continuous patch that is suitable for heparin binding.

Glycosaminoglycans are ubiquitously present on almost all mammalian cells and this class of carbohydrates are central to the strategy employed by *coronaviridae* to attach to host cells. Heparin has previously been shown to inhibit SARS-associated coronavirus strain HSR1 cell invasion^{2,18} and this, in concert with the data presented within this study, supports the utilisation of glycosaminoglycan-derived pharmaceuticals against SARS-associated coronavirus. Furthermore, this study strongly supports the repurposing of heparin and its derivatives as antiviral agents, providing a rapid countermeasure against the current SARS-CoV-2 outbreak.

It is noteworthy that even pharmaceutical-grade heparin preparations remain a polydisperse mixture of natural products, containing both anticoagulant and non-anticoagulant saccharide structures. The latter may prove to be an invaluable resource for next-generation, biologically active, antiviral agents that display negligible anticoagulant potential, whilst the former remains tractable to facile, chemical (and enzymatic) engineering strategies to ablate their anticoagulation activities.

The subfractionation of existing heparin preparations against anticoagulant activities (with proven low-toxicity profiles, good bioavailability and industrial-scale manufacturing) for off-label pathologies, provides an attractive strategy for quickly and effectively responding to COVID-19 and for the development of next generation heparin-based therapeutics.

Such drugs will be amenable to routine parenteral administration through currently established routes and additionally, direct to the respiratory tract via nasal administration, using nebulised heparin, which would be unlikely to gain significant access to the circulation. Thus, the anticoagulant activity of heparin, which can in any event be engineered out, would not pose a problem. Importantly, such a route of administration would not only be suitable for prophylaxis, but also for patients under mechanical ventilation¹⁹.

References

1. Herpes Simplex Virus Types 1 and 2 Differ in Their Interaction with Heparan Sulfate. Trybala E, Liljeqvist JA, Svennerholm B, Bergström T. *J Virol.* 2000 Oct;74(19):9106-14.
2. Coronaviridae and SARS-associated coronavirus strain HSR1. Vicenzi E, Canducci F, Pinna D, Mancini N, Carletti S, Lazzarin A, Bordignon C, Poli G, Clementi M. *Emerging infectious diseases.* 2004 vol: 10 (3) pp: 413-418.
3. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Ghezzi S, Cooper L, Rubio A, Pagani I, Capobianchi M, Ippolito G, Pelletier J, Meneghetti M, Lima M, Skidmore M, Broccoli V, Yates E, Vicenzi E. *Antiviral Research* 2017 vol: 140 pp:13-17.
4. Subverting the mechanisms of cell death: Flavivirus manipulation of host cell responses to infection. Vicenzi E, Pagani I, Ghezzi S, Taylor S, Rudd T, Lima M, Skidmore M, Yates E. *Biochemical Society Transactions* 2018 vol: 46 (3) pp: 609-617.
5. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. WuDunn D, Spear P. *Journal of Virology.* 1989 vol: 63 (1) pp: 52-58.
6. Inhibition of influenza H5N1 invasion by modified heparin derivatives. Skidmore M, Kajaste-Rudnitski A, Wells N, Guimond S, Rudd T, Yates E, Vicenzi E. *MedChemComm.* 2015 vol: 6 (4) pp: 640-646.
7. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albin A, Noonan D, D'Adda Di Fagagna F, Giacca M, Presta M. *Journal of Biological Chemistry.* 1997 vol: 272 (17) pp: 11313-11320.
8. Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. Harrop H, Rider C. *Glycobiology.* 1998 vol: 8 (2) pp: 131-137.
9. Human Coronavirus NL63 Utilizes Heparan Sulfate Proteoglycans for Attachment to Target Cells. Milewska A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K. *Journal of Virology.* 2014 vol: 88 (22) pp: 13221-13230.
10. Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy. Micsonai A, Wien F, Kernya L, Lee Y, Goto Y, Réfrégiers M, Kardos J. *Proceedings of the National Academy of Sciences of the United States of America.* 2015 vol: 112 (24) pp: E3095-E3103.
11. Influence of substitution pattern and cation binding on conformation and activity in heparin derivatives. Rudd T, Guimond S, Skidmore M, Duchesne L, Guerrini M, Torri G, Cosentino C, Brown A, Clarke D, Turnbull J, Fernig D, Yates E. *Glycobiology.* 2007 vol: 17 (9) pp:983-993.

12. The potential for circular dichroism as an additional facile and sensitive method of monitoring low-molecular-weight heparins and heparinoids. Rudd T, Skidmore M, Guimond S, Holman J, Turnbull J, Lauder R, Fernig D, Yates E. *Thrombosis and Haemostasis*. 2009 vol: 102 (5) pp:874-878.
13. Robust ligand shells for biological applications of nanoparticles. Duchesne L, Gentili D, Franchini M C, Fernig D G. *Langmuir*. 2008 vol: 24 pp: 13572-13580.
14. A quartz crystal microbalance method to study the terminal functionalization of glycosaminoglycans. Thakar D, Migliorini E, Coche-Guerente L, Sadir R, Lortat-Jacob H, Boturyn D, Renaudet O, Labbe P, Richter R P. *Chem Commun*. 2014 vol: 50 (96) pp:15148-15151.
15. Well-defined biomimetic surfaces to characterize glycosaminoglycan-mediated interactions on the molecular, supramolecular and cellular levels. Migliorini E, Thakar D, Sadir R, Pleiner T, Baleux F, Lortat-Jacob H, Coche-Guerente L, Richter R P. *Biomaterials*. 2014 vol: 35 (32) pp:8903-8915.
16. Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Delehedde M, Lyon M, Gallagher J T, Rudland P S, Fernig D G. *Biochem J*. 2002 vol: 366 (1) pp:235-44.
17. Antithrombin stabilisation by sulfated carbohydrates correlates with anticoagulant activity. Lima M, Hughes A, Veraldi N, Rudd T, Hussain R, Brito A, Chavante S, Tersariol I, Siligardi G, Nader H, Yates E. *MedChemComm*. 2013 vol: 4 (5) pp: 870-873.
18. Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans. Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G, Jiang C. *PLoS ONE*. 2011 vol: 6 (8) pp: e23710.
19. Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysis. Glas GJ, Serpa Neto A, Horn J, Cochran A, Dixon B, Elamin EM, Faraklas I, Dissanaike S, Miller AC, Schultz MJ. *Ann Intensive Care*. 2016 vol: 6 (1) pp:33.